In line with findings for other immunomodulatory antibodies, e.g., anti-CTLA-4 (30), recent preclinical data obtained in a syngeneic mouse tumor model highlight the contribution of the Fc domain for the functionality of anti-PD-L1 antibodies and suggests that the anti-tumor response of anti-PD-L1 antibodies is at least partially dependent on engagement of activating FcγRs (13). Here, CTLA4 is linked to neoplasm.